UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News AbbVie's Venclyxto approved in Europe in CLL AbbVie blood cancer drug tipped to be a blockbuster.
News AZ's Tagrisso shines in lung cancer trial Phase 3 trial supports Tagrisso as "standard of care" for some patients
News Kite in CAR-T pole position as rolling submission begins Kite to start filing data for KTE-C19 with US regulator.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
